Itratuf Capsule contains Itraconazole 100 mg, a broad-spectrum triazole antifungal agent used for the treatment of various fungal infections. Itraconazole works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting cell membrane integrity and leading to fungal cell death. It is indicated for the management of systemic and superficial mycoses including aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and candidiasis. Itratuf Capsule is typically administered orally and should be taken with food to enhance absorption. The dosage and duration of therapy depend on the type and severity of infection, as well as patient response. Common adverse effects include gastrointestinal disturbances such as nausea, vomiting, abdominal pain, and diarrhea, as well as headache and dizziness. Caution is advised in patients with hepatic impairment, and liver function tests should be monitored during prolonged therapy. Itratuf may interact with several drugs metabolized by the cytochrome P450 system; therefore, a thorough medication review is essential before initiation. This medication is contraindicated in patients with known hypersensitivity to itraconazole or other azole antifungals. Use during pregnancy is not recommended unless the potential benefit outweighs the risk.